Publications

See a complete PubMed list of publications by Shlomo Melmed, MB, ChB.

Selected Key Publications

Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol. 2016 Feb;12(2):90-98. http://www.nature.com/nrendo/journal/v12/n2/full/nrendo.2015.196.html.

Chesnokova V, Zonis S, Zhou C, Recouvreaux MV, Ben-Shlomo A, Araki T, Barrett R, Workman M, Wawrowsky K, Ljubimov VA, Uhart M, Melmed S. Growth hormone is permissive for neoplastic colon growth. Proc Natl Acad Sci USA. 2016 Jun;113(23):E32590-32599. http://www.pnas.org/content/113/23/E3250.abstract.

Liu NA, Araki T, Cuevas-Ramos D, Hong J, Ben-Shlomo A, Tone Y, Tone M, Melmed S. Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease. J Clin Endocrinol Metab. 2015;100(7):2557-2564. http://press.endocrine.org/doi/10.1210/jc.2015-1606.

Zhou C, Jiao Y, Wang R, Ren SG, Wawrowsky K, Melmed S. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. J Clin Invest. 2015;125(4):1692-1702. http://www.jci.org/articles/view/78173.

Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter Phase III trial. J Clin Endocrinol Metab. 2015;100(4):1699-1708. http://press.endocrine.org/doi/10.1210/jc.2014-4113.

Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed S. A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2015;100(1):122-131. http://press.endocrine.org/doi/abs/10.1210/jc.2014-2468.

Melmed S, Kleinberg DL, Bonert V, Fleseriu M. Acromegaly: assessing the disorder and navigating therapeutic options for treatment. Endocr Pract. 2014 Oct;20 Suppl 1:7-17; quiz 18-20. http://journals.aace.com/doi/abs/10.4158/EP14430.RA.

Ben-Shlomo A, Mirocha J, Gwin SM, Khine AK, Liu NA, Sheinin RC, Melmed S. Clinical factors associated with biochemical adrenal-cortisol insufficiency in hospitalized patients. Am J Med. 2014;127(8):754-762. http://www.amjmed.com/article/S0002-9343(14)00226-5/abstract.

Eigler T, Ben-Shlomo A, Zhou C, Khalafi R, Ren SG, Melmed S. Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis. Mol Endocrinol. 2014;28(4):554-564. http://press.endocrine.org/doi/abs/10.1210/me.2013-1327.

Chesnokova V, Zhou C, Zonis S, Tani Y, Ben-Shlomo A, Ren SG, Melmed S. Growth hormone is a cellular senescence target in pituitary and non-pituitary cells. Proc Natl Acad Sci USA. 2013 Aug;110(35):E3331-3339. http://www.pnas.org/content/110/35/E3331.

Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, Melmed S. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest. 2011 Dec;121(12):4712-4721. http://www.jci.org/articles/view/60417.

Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S, Melmed S. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci USA. 2011 May 17;1808(20):8414-8419. http://www.pnas.org/content/108/20/8414.

Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009 Nov;119(11):3189-3202. http://www.jci.org/articles/view/39375.

Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab. 2009 Nov;94(11):4342-4350. http://press.endocrine.org/doi/abs/10.1210/jc.2009-1311.

Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S. p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA. 2008 Nov;105(45):17498-17503. http://www.pnas.org/content/105/45/17498.

Melmed S. Medical progress: acromegaly. N Eng J Med. 2006 Dec;355(24):2558-2573. http://www.nejm.org/doi/full/10.1056/NEJMra062453.

Ben-Shlomo A, Wawrowsky KA, Proekt I, Wolkenfeld NM, Ren SG, Taylor J, Culler MD, Melmed S. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of ACTH secretion. J Biol Chem. 2005 Jun;280(25):24011-24021. http://www.jbc.org/content/280/25/24011.long.

Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004 Aug;114(3):349-356. http://www.jci.org/articles/view/19933.

Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med. 1999 Nov;5(11):1317-1321. http://www.nature.com/nm/journal/v5/n11/full/nm1199_1317.html.

FmdkZG1tbHgHYXgBZ2VlYngGZmNheBNnZGRtZWc=